News & Events
News & Events
November 10, 2022
C-Path and EFACTS Announce Data Sharing Agreement Making RDCA-DAP the Largest Worldwide Database for Friedreich’s Ataxia
C-Path and EFACTS today announced a data sharing agreement to incorporate patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), solidifying RDCA-DAP as the largest worldwide database for Friedreich’s ataxia.
November 2, 2022
C-Path and Eisai Data Sharing Collaboration to Include Lennox-Gastaut Syndrome Registry and Clinical Trial DataTUCSON, Ariz., Nov. 2, 2022 — Critical Path Institute (C-Path) and the Eisai Co., Ltd. (Eisai) today announced a joint collaboration to significantly promote data sharing and incorporate Lennox-Gastaut Syndrome (LGS) clinical trial data, into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®). Lennox-Gastaut syndrome is a severe form of epilepsy with seizures occurring...
October 20, 2022
C-Path’s Ramona Walls Promoted to Executive Director of Data Science
C-Path has named Ramona L. Walls, Ph.D., as Executive Director of Data Science within C-Path’s Data Collaboration Center (DCC).
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
September 15, 2022
Rare Disease Workshop Highlights the Importance of Data Sharing in Drug Development
RDCA-DAP® hosted an all-day workshop and annual meeting September 13 and 14 in Washington. The in-person and livestream event for rare disease stakeholders featured expert presentations, panel discussions, platform demonstrations, and was attended by more than 200 patients, researchers, clinicians, biopharmaceutical company representatives, regulatory reviewers and scientists.